Compare CD & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CD | SGHT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Computer Software: Programming Data Processing | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 382.5M | 309.6M |
| IPO Year | N/A | 2021 |
| Metric | CD | SGHT |
|---|---|---|
| Price | $2.67 | $7.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 140.0K | ★ 175.4K |
| Earning Date | 08-31-2023 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.73 | $3.19 |
| 52 Week High | $14.10 | $9.24 |
| Indicator | CD | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 78.53 |
| Support Level | $2.96 | $6.56 |
| Resistance Level | $3.22 | $8.93 |
| Average True Range (ATR) | 0.23 | 0.45 |
| MACD | 0.11 | 0.15 |
| Stochastic Oscillator | 56.52 | 97.10 |
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.